Gaps in treatment amongst metastatic castration resistant prostate cancer (mCRPC) patients taking abiraterone acetate or enzalutamide.

被引：0
|
作者：
Behl, Ajay
Ellis, Lorie
Pilon, Dominic
Xiao, Yongling
Lefebvre, Patrick
Dawson, Nancy Ann
机构：
[1] Janssen Sci Affairs LLC, Horsham, PA USA
[2] 1000 Gauchetiere Ouest, Montreal, PQ, Canada
[3] Grp Anal Ltee, Montreal, PQ, Canada
[4] Lombardi Comprehens Canc Ctr, Washington, DC USA
来源：
JOURNAL OF CLINICAL ONCOLOGY | 2016年 / 34卷 / 02期
关键词：
D O I：
10.1200/jco.2016.34.2_suppl.334
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
334
引用
收藏
页数：1
相关论文
共 50 条
  • [21] Cabazitaxel in metastatic castrate resistant prostate cancer (mCRPC) in the era of enzalutamide (ENZA) and abiraterone acetate (AA).
    Body, Amy
    Pranavan, Gane
    Malik, Laeeq
    JOURNAL OF CLINICAL ONCOLOGY, 2017, 35
  • [22] Results of a phase II trial of selinexor, an oral selective inhibitor of nuclear export (SINE), in patients with metastatic castration resistant prostate cancer (mCRPC) refractory to abiraterone or enzalutamide.
    Wei, Xiao
    Siegel, Adam Phillip
    Aggarwal, Rahul Raj
    Lin, Amy M.
    Friedlander, Terence W.
    Fong, Lawrence
    Paraganlija, Mirela
    Chang, Emily
    Zhang, Li
    Ryan, CharlesJ.
    JOURNAL OF CLINICAL ONCOLOGY, 2017, 35
  • [23] Treatment duration and utilization patterns in metastatic castration-resistant prostate cancer patients receiving enzalutamide or abiraterone acetate.
    Kassabian, Vahan
    Flanders, Scott
    Wilson, Samuel
    Brown, Bruce A.
    Song, Yan
    Yang, Hongbo
    Lechpammer, Stanislav
    Schultz, Neil M.
    JOURNAL OF CLINICAL ONCOLOGY, 2018, 36 (06)
  • [24] Enzalutamide versus Abiraterone Acetate as first-line treatment of castration resistant metastatic prostate cancer in geriatric (≥75) patients
    Alkan, Ali
    Guc, Zeynep Gulsum
    Gurbuz, Mustafa
    ozgun, Guliz
    Degirmencioglu, Serkan
    Dogan, Mutlu
    Telli, Tugba Akin
    Keskin, Ozge
    Arslan, Cagatay
    Bilgin, Burak
    Goksu, Sema Sezgin
    Demir, Hacer
    Koksoy, Elif Berna
    Kostek, Osman
    Erturk, Ismail
    Sakalar, Teoman
    Yasar, Arzu
    Turkkan, Gorkem
    Kasim, Bu ra
    Karaoglu, Aziz
    oksuzoglu, Berna cakmak
    Yumuk, Fulden
    Sendur, Mehmet Ali
    Coskun, Hasan Senol
    cicin, Irfan
    Karadurmu, Nuri
    Tanriverdi, Ozgur
    Akbulut, Hakan
    Urun, Yuksel
    JOURNAL OF MENS HEALTH, 2021, 17 (04) : 128 - 134
  • [25] Clinical activity of abiraterone acetate in patients with metastatic castration-resistant prostate cancer progressing after enzalutamide
    Noonan, K. L.
    North, S.
    Bitting, R. L.
    Armstrong, A. J.
    Ellard, S. L.
    Chi, K. N.
    ANNALS OF ONCOLOGY, 2013, 24 (07) : 1802 - 1807
  • [26] Serial genotypic characterization of circulating tumor cells (CTCs) in patients with metastatic castration resistant prostate cancer (mCRPC) undergoing treatment with abiraterone acetate (abi) or enzalutamide (enza)
    Dizman, N.
    Patel, J.
    He, M.
    Foulk, B.
    Smirnov, D. A.
    Hsu, J.
    Twardowski, P.
    Kortylewski, M.
    Bhargava, V.
    Jones, J.
    Pal, S. K.
    ANNALS OF ONCOLOGY, 2017, 28
  • [27] Comparison of abiraterone and enzalutamide in patients with metastatic castration-resistant prostate cancer in Taiwan
    Ni, Hsueh Fen
    Li, Jian-Ri
    INTERNATIONAL JOURNAL OF UROLOGY, 2022, 29 : 60 - 60
  • [28] Impact of 68Ga-PSMA PET/CT in patients with metastatic castration-resistant prostate cancer (mCRPC) treated with enzalutamide.
    Altavilla, Amelia
    Caroli, Paola
    Giunta, Emilio Francesco
    Scarpi, Emanuela
    Rossetti, Virginia
    Casadei, Chiara
    Lolli, Cristian
    Schepisi, Giuseppe
    Bleve, Sara
    Cursano, Maria Concetta
    Gasperoni, Lorenzo
    Matteucci, Federica
    De Giorgi, Ugo
    JOURNAL OF CLINICAL ONCOLOGY, 2023, 41
  • [29] ABIraterone (ABI) and ENZalutamide (ENZ) induce changes in immunologic profile of patients with metastatic castration-resistant prostate cancer (mCRPC)
    Salgia, Meghan
    Perez, Marc L.
    Jones, Jeremy
    Won, Hae Jung
    Poroyko, Valeriy
    Twardowski, Przemyslaw
    Kortylewski, Marcin
    Pal, Sumanta K.
    CANCER RESEARCH, 2017, 77
  • [30] Indirect comparison between abiraterone acetate and enzalutamide for the treatment of metastatic castration-resistant prostate cancer: a systematic review
    Zhang, Wei
    Wu, Teng-Yun
    Chen, Qi
    Shi, Xiao-Lei
    Xiao, Guang-An
    Zhao, Lin
    Xu, Chuan-Liang
    Zhou, Tie
    Sun, Ying-Hao
    ASIAN JOURNAL OF ANDROLOGY, 2017, 19 (02) : 196 - 202
12345